THERAPY FOR CANINE LEISHMANIOSIS

Current treatment protocols for CanL

DRUGS DOSE MAIN SIDE EFFECTS
Meglumine antimoniate (a) 100 mg/kg SC, SID or divided in two doses, for 4-6 weeks (initial reduced dosages for 2-3 days may be useful to detect any adverse events) (b) Potential nephrotoxicity
Pain and inflammation at injection site
Miltefosine (a) 2 mg/kg PO, once a day for 28 days Vomiting
Diarrhea
Allopurinol 10 mg/kg PO, twice a day for at least 6-12 months Xanthine urolithiasis
Domperidone (c) 0,5 mg/kg PO, once a day for 1 month Galactorrhea

PO: per os; SC: subcutaneous

(a) Registered for veterinary use in most European countries; both drugs are recommended in combination with allopurinol.
(b) There is a limited number of studies on optimal treatment regimen.
Recommended dosages off-label but according to pharmacokinetic and clinical studies in dogs.
Treatment prolongation by 2-3 weeks may be considered if patient improvement is insufficient.
(c) Only considered for Stage I.

 

Disclaimer: Information given here on drugs and dosages are based on a consensus of clinical and scientific experience by the LeishVet members. These recommendations have been published in scientific peer-reviewed scientific journals. Veterinary practitioners are requested to check with product leaflets and product registrations in their related country prior to any product selection and initiation of treatment.